Document is current
Any future updates will be listed below
-
Authors
Park, Hyejin https://orcid.org/0009-0009-3494-0141
Kam, Tae-In https://orcid.org/0000-0002-7241-4902
Dawson, Valina L. https://orcid.org/0000-0002-2915-3970
Dawson, Ted M. https://orcid.org/0000-0002-6459-0893
- License Information
-
More Information
Article History
Accepted: 31 October 2024
First Online: 28 November 2024
Competing interests
: T.M.D. owns stock in Aevum Therapeutics and stock options in D&D Pharmatech, Inhibikase Therapeutics and Ventyx Biosciences; holds equity in D&D Pharmatech; is compensated for his role on the scientific advisory boards of Aevum and Ventyx; is entitled to royalties from AbbVie; and is a founder and inventor of technology for Neuraly, which is now a subsidiary of D&D Pharmatech. V.L.D. owns stock options in D&D Pharmatech and Inhibikase Therapeutics; holds equity in D&D Pharmatech; and is a founder and inventor of technology for Neuraly, which is now a subsidiary of D&D Pharmatech. The other authors declare no competing interests.
